ProfoundBio

ProfoundBio Raises $112M Series B

Clinical-stage oncology company developing antibody-drug conjugates (ADCs) for targeted cancer therapy

Key Highlights

• Funding Amount: $112M Series B
• Valuation: Undisclosed
• Headquarters: Seattle, WA
• Founded: 2020
• Employees: 80-150
• Total Raised: $165M

About the Funding Round

ProfoundBio has successfully closed $112M Series B in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

• Ally Bridge Group
• T. Rowe Price
• OrbiMed

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help ProfoundBio achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. ProfoundBio's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2020 and headquartered in Seattle, WA, ProfoundBio has established itself as an innovative player in the biotech space. With 80-150 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, ProfoundBio plans to:

• Accelerate product development and innovation
• Expand into new markets and geographies
• Grow the team across engineering, sales, and operations
• Strengthen partnerships with key industry players
• Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in ProfoundBio's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about ProfoundBio, visit their website or contact their press office.